| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JTHO.2016.02.015 |
| P8608 | Fatcat ID | release_bfzrpwvpfjdhbebvwpy6fh4rka |
| P932 | PMC publication ID | 7179759 |
| P698 | PubMed publication ID | 26944305 |
| P5875 | ResearchGate publication ID | 296621161 |
| P2093 | author name string | David P Carbone | |
| Takehito Shukuya | |||
| P2860 | cites work | DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. | Q37681615 |
| The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. | Q38355766 | ||
| PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer | Q38373841 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. | Q40735960 | ||
| PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. | Q40889616 | ||
| Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer | Q42057288 | ||
| Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59274003 | ||
| B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 | ||
| Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers | Q24611043 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice | Q28201627 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | Q30356434 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| Tissue expression of PD-L1 mediates peripheral T cell tolerance. | Q36228541 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Genomic landscape of non-small cell lung cancer in smokers and never-smokers | Q36851245 | ||
| Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer | Q37087884 | ||
| P433 | issue | 7 | |
| P921 | main subject | lung cancer | Q47912 |
| antibody | Q79460 | ||
| P304 | page(s) | 976-988 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer | |
| P478 | volume | 11 |
| Q91830069 | A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer |
| Q55229901 | A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. |
| Q64113478 | A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab |
| Q102320153 | A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients |
| Q98475324 | A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma |
| Q52562762 | APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. |
| Q94453578 | Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy |
| Q97539880 | Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing |
| Q96304660 | Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28 |
| Q58795231 | Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies |
| Q83226948 | Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction |
| Q47102822 | Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer |
| Q38675969 | Atezolizumab for the treatment of non-small cell lung cancer |
| Q58804389 | Autochthonous murine models for the study of smoker and never-smoker associated lung cancers |
| Q92981847 | Autophagy-related genes prognosis signature as potential predictive markers for immunotherapy in hepatocellular carcinoma |
| Q38844239 | Biomarker development in the precision medicine era: lung cancer as a case study. |
| Q90519843 | Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients |
| Q38696133 | Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study |
| Q38868396 | Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers |
| Q94552708 | Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer |
| Q55287125 | Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. |
| Q92424850 | Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort |
| Q61810141 | Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors |
| Q91596444 | Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles |
| Q64106051 | Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence |
| Q94570569 | Effects of wogonoside on invasion and migration of lung cancer A549 cells and angiogenesis in xenograft tumors of nude mice |
| Q47249076 | Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort. |
| Q90737588 | Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives |
| Q98906809 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer |
| Q52682751 | Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy |
| Q87696185 | Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer |
| Q38819349 | Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology |
| Q55008531 | Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). |
| Q90752334 | In vitro and in vivo synergistic efficacy of ceritinib combined with PD-L1 inhibitor in ALK-rearranged NSCLC |
| Q37308194 | Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy |
| Q89654099 | Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report |
| Q38877810 | Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape |
| Q42398020 | Major milestones in translational oncology. |
| Q51759206 | Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. |
| Q38666241 | Monitoring immune-checkpoint blockade: response evaluation and biomarker development |
| Q61809756 | Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer |
| Q91853978 | Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report |
| Q92960661 | PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells |
| Q47422615 | PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer |
| Q39036924 | PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients |
| Q90475606 | PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy |
| Q39102913 | PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. |
| Q89798453 | Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report |
| Q90437162 | Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer |
| Q99582693 | Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors |
| Q94453258 | Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer |
| Q49163406 | Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer |
| Q92319984 | Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System |
| Q61884094 | RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients |
| Q64118104 | Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer |
| Q93126534 | Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy |
| Q92925142 | The immune response-related mutational signatures and driver genes in non-small-cell lung cancer |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q57067759 | The intracellular signalosome of PD-L1 in cancer cells |
| Q28069924 | The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 |
| Q92692373 | What can artificial intelligence teach us about the molecular mechanisms underlying disease? |
| Q58599652 | Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer |
Search more.